Sermorelin cycle length: how long protocols actually run

Last updated 2026-07-24

What does a typical sermorelin cycle length look like?

Most prescribers who use sermorelin for adults run it in blocks of roughly 3 to 6 months, then reassess with bloodwork and a conversation about symptoms before deciding whether to continue, adjust the dose, or stop. There's no single official schedule for this because sermorelin's only FDA-approved use was the pediatric growth hormone deficiency stimulation test and the discontinued adult product Geref, not an ongoing adult replacement protocol with a labeled duration. That means "cycle length" in the adult, off-label context is really a prescribing convention built from how the peptide works physiologically, not a number pulled from a package insert. Sermorelin is a growth hormone releasing hormone (GHRH) analog. It prompts the pituitary to release its own growth hormone in a pulsatile pattern, rather than replacing GH directly ^[1]. Because it depends on a working pituitary, response builds gradually over weeks, and prescribers generally want at least 8 to 12 weeks before judging whether it's doing anything measurable. Some clinics run continuous dosing for 6 months and stop. Others cycle 5 days on, 2 off, or run months-on/months-off patterns modeled loosely on how the peptide was dosed in pediatric GHD trials. None of this is standardized across the field, which is exactly why the conversation with your prescriber about what they're tracking and why matters more than the calendar length itself.

Why isn't there an official sermorelin dosing schedule for adults?

Because the FDA-approved use never covered adult, ongoing therapy. Sermorelin's branded form, Geref, was approved for diagnostic testing of growth hormone deficiency in children and briefly for adult GHD management, then discontinued by the manufacturer for business reasons. It was not withdrawn over a safety signal, which is a meaningfully different story than most compounded peptides can tell [1, 2]. Today, sermorelin used for adults is almost always dispensed through compounding pharmacies under 21 U.S.C. 353a, the federal statute governing pharmacy compounding ^[2]. The FDA maintains lists of bulk substances that compounders may legally use under section 503A and 503B of the FD&C Act [4, 5], and the specific mixture of what's permitted has shifted over time as the agency reviews nominations ^[3]. Because there's no FDA-approved labeling to govern adult dosing or duration, the cycle length you're offered depends entirely on the individual prescriber's protocol, their clinical experience, and how conservative they are about running compounded peptides long-term without long-duration safety data in this population.

How long before sermorelin starts working?

Clinical reviews describing sermorelin's mechanism note that because it works through the body's own pituitary-GHRH axis rather than delivering GH directly, changes in downstream markers like IGF-1 build over weeks, not days ^[1]. A study in hypogonadal men using GH secretagogues found measurable increases in serum IGF-1 with treatment, supporting the idea that the axis does respond, though this doesn't tell you what happens with symptoms like sleep quality or energy on any fixed timeline . Most prescribers don't order bloodwork before 8 weeks. Checking earlier is mostly wasted money, since single-pulse GH secretion is noisy and IGF-1 (a more stable proxy) needs time to shift. If a 3-month block shows no meaningful IGF-1 movement and no symptom change, that's useful information: either the dose needs adjusting, or the person isn't a good candidate for this class of therapy, and continuing to guess for another 6 months on faith isn't a good use of a prescription budget.

What determines how long a sermorelin cycle should run?

Three things drive this in practice: baseline IGF-1 and clinical picture, response after the first block, and how the prescriber weighs unknowns around long-term compounded peptide use. There's genuinely more research interest right now in peptides for musculoskeletal and orthopedic applications broadly, with a 2026 review in the Journal of the American Academy of Orthopaedic Surgeons cataloging therapeutic peptide use across orthopedic contexts and flagging both promise and real evidence gaps ^[4]. A related 2026 Sports Medicine review specifically examined safety and efficacy data for approved and unapproved peptide therapies used for musculoskeletal injury and athletic performance, another area where cycle length questions come up often and the evidence is thinner than marketing suggests ^[5]. Neither of those reviews is sermorelin-specific in a way that gives you a hard number for cycle duration. What they do make clear is that peptide protocols in general are being run on incomplete long-term data, and prescribers who are being careful tend to build in reassessment points rather than open-ended continuous use. A prescriber weighing all this will typically set an initial trial length (often 3 months), a follow-up lab draw, and explicit criteria for stopping: no IGF-1 change, new side effects, or a patient who simply doesn't want to continue an injectable regimen indefinitely.

Do you need to cycle off sermorelin, or can you take it continuously?

There's no controlled long-term human trial establishing what happens with years of continuous sermorelin use in adults, which is exactly why most clinics build in breaks rather than running it indefinitely. The rationale echoes older pituitary physiology research: GHRH-driven GH secretion is naturally pulsatile, and studies going back decades on GH-releasing factor physiology (including work on maternal and fetal GH secretion patterns) describe the pulsatile nature of this axis as a basic feature of how it's regulated, not an accident . Whether a scheduled break actually preserves pituitary responsiveness better than continuous dosing hasn't been tested head to head in adults on sermorelin specifically. Prescribers who cycle off are mostly following a cautious, symptom-and-labs-driven approach rather than citing a specific study that proves cycling is necessary. If your prescriber recommends a break, ask what they're watching for when you restart, and if they don't recommend one, ask why they're comfortable with continuous use given how thin the long-duration data is.

Sermorelin cycle length versus HGH dosing duration: what's the real difference?

This is usually the actual question behind "how long should my cycle be." HGH (recombinant human growth hormone, like somatropin) is FDA-approved for specific adult indications including confirmed adult growth hormone deficiency, and it is dosed continuously, often daily, for as long as the diagnosis and monitoring support it, sometimes for years, under an endocrinologist's ongoing supervision through Drugs@FDA-listed approved products . Sermorelin doesn't have that same approved, ongoing-adult-use framework. It's a GHRH analog, meaning it stimulates your own pituitary rather than replacing GH molecule-for-molecule ^[1]. That has two practical consequences for cycle length. First, sermorelin can't overwhelm the pituitary's own feedback loops the way exogenous GH can, which is part of why some prescribers consider it gentler, though "gentler" isn't the same as "proven effective for the same outcomes." Second, because there's no approved adult dosing label to follow, sermorelin cycle length is set by clinical convention, not regulatory precedent, while HGH duration for approved indications follows a much more established monitoring pathway. If you're comparing the two head to head for symptoms of low GH in adulthood, the honest answer is that sermorelin has a real but narrower and older evidence base (mostly built around pediatric GHD diagnosis and modest adult data), while HGH has a larger, FDA-reviewed evidence base for confirmed adult GHD specifically. Sermorelin is not a proven substitute for HGH in a diagnosed deficiency; it's a different mechanism with different, generally more limited data. For a fuller breakdown of what sermorelin does and doesn't have evidence for, see sermorelin.

What happens if you stop sermorelin after a cycle?

Because sermorelin doesn't replace GH directly, stopping it means your pituitary goes back to whatever baseline pulsatile pattern it had before treatment, not a hard crash the way abruptly stopping some hormone therapies can feel. There isn't good long-term human data specifically tracking IGF-1 or symptom rebound after stopping sermorelin in adults, so anyone telling you exactly what to expect after cycle 3 is extrapolating from theory more than data. What a reasonable prescriber will do is repeat labs a few weeks after stopping to see where IGF-1 lands, compare it to your pre-treatment baseline, and use that to decide whether restarting makes sense or whether the original block accomplished what it could. If you noticed sleep or energy changes during the cycle and they fade quickly after stopping, that's useful signal about how dependent the effect was on continued dosing versus a lasting shift. For a look at what "working" versus "not working" tends to look like across a cycle, see sermorelin peptide before and after.

Can you stack sermorelin with other peptides during a cycle, and does that change duration?

Combination protocols exist in practice (sermorelin paired with a GHRP like ipamorelin, or with tesamorelin, another GHRH analog), and the pitch is usually that a GHRH plus a separate secretagogue pathway can produce a bigger GH pulse than either alone. That combination logic has real pharmacology behind it, but it also means you're now running two compounded, non-FDA-approved-for-this-use substances together with even less combined safety data than either has alone. A 2020 review on growth hormone secretagogues in hypogonadal men's body composition management discusses this class of combination approach in the context of managing metabolic and body composition outcomes, without establishing a standard duration for stacked use ^[6]. If a prescriber suggests stacking, that's a reasonable question to push on: what does adding the second peptide change about how long the cycle should run, and what extra monitoring does it require? Details on this specific combination are covered in can stack tesamorelin and sermorelin.

What monitoring should happen during a sermorelin cycle?

At minimum: baseline IGF-1 before starting, a repeat draw at 8 to 12 weeks, and a symptom check-in that isn't just "do you feel younger" but something concrete like sleep quality, recovery from exercise, or specific complaints that prompted treatment in the first place. Some prescribers also track fasting glucose given growth hormone axis activity's relationship to insulin sensitivity, though this isn't universal practice. What you should not do is judge a cycle by symptoms alone with no labs at all. IGF-1 is the standard proxy used in the endocrinology literature for GH axis activity because direct GH measurement is too pulsatile and short-lived to be practical for routine monitoring . If your provider isn't drawing labs at least once during a 3 to 6 month cycle, ask why, because "trust the process" isn't a monitoring plan.

Is a longer sermorelin cycle safer or riskier than a shorter one?

Neither direction has strong data behind it specifically for sermorelin in adults, which is an honest but unsatisfying answer. What we do have are adjacent signals worth taking seriously. A 2026 case report described anterior cervical osteophyte-related dysphagia in a long-term growth hormone user, illustrating that prolonged elevation of GH axis activity can, in rare individual cases, be linked to unusual musculoskeletal complications over years of use . That case wasn't about sermorelin specifically and doesn't prove causation broadly, but it's a data point supporting the general caution that indefinite, unmonitored GH axis stimulation isn't automatically benign just because sermorelin works through a "more natural" pathway than injected GH. Separately, a 2021 case report explored sermorelin as a potential treatment approach in recurrent glioma, an entirely different clinical context from cosmetic or wellness use, and not evidence that longer wellness-context cycles are either more effective or riskier ^[7]. It's included here only to show how narrow and mixed the actual sermorelin literature is; there isn't a body of long-duration adult safety trials to draw firm cycle-length conclusions from either way. The practical takeaway: shorter, monitored cycles with clear stopping criteria are the more defensible default precisely because nobody has good long-duration safety data to justify running it open-ended. For a longer look at what's known and unknown about extended use, see sermorelin long-term side effects.

How do you know if sermorelin is even legitimate and properly sourced during your cycle?

This matters more for sermorelin than for many other prescription drugs because it's compounded, not manufactured under an FDA-approved brand anymore. Compounded sermorelin is legal for a prescriber to prescribe and a licensed pharmacy to dispense under 21 U.S.C. 353a ^[2], but the raw material still has to be on FDA's list of substances permitted for compounding under 503A or sourced through a registered 503B outsourcing facility [4, 5]. Outside legitimate pharmacy channels, there's a documented problem with falsified biopharmaceutical injectables circulating in gray markets. A 2016 European surveillance study, "Operation Resistance," documented falsified antibiotics and biopharmaceutical injectables moving through illegitimate distribution channels, a reminder that injectable peptides bought outside licensed pharmacy supply chains carry real authentication risk, separate from any question about the drug's own safety profile . Anti-doping laboratories have also had to build increasingly sensitive detection methods (nanoLC-HRMS/MS methods capable of picking up GHRH-class peptides at low picogram-per-mL concentrations in urine) specifically because synthetic GHRH analogs have shown up in performance contexts outside legitimate prescribing [11, 17]. None of that is about sermorelin's safety when properly prescribed; it's about why sourcing through a licensed pharmacy, not a gray-market seller, is the whole ballgame for knowing what's actually in the vial. Sermorelin Co connects the provider-reviewed prescribing route to fulfillment through a licensed pharmacy partner, which is the sourcing lane that avoids this problem entirely. For more on vetting sources generally, see best place to buy sermorelin and sermorelin reviews.

What should you ask your prescriber before starting a cycle?

Ask for the specific length they're proposing and why (3 months versus 6), what labs they'll draw and when, what specific symptom or lab change would make them extend the cycle versus stop it, and whether they're recommending any break before a second cycle. Ask what pharmacy is compounding the product and whether it's a 503A or 503B facility, since that affects both quality oversight and, in some cases, insurance or cost structure. If a provider can't give you a monitoring plan beyond "see how you feel," that's worth pausing on. Sermorelin's mechanism (stimulating a natural pituitary pathway) genuinely differs from directly injecting HGH, and that difference is real and worth understanding ^[1], but it doesn't mean the therapy is risk-free or that duration doesn't matter. A specific timeline, specific lab thresholds, and a specific plan for what happens if nothing changes at 3 months is the bar for a reasonable provider-reviewed protocol, whether you're getting it through Sermorelin Co or another provider-reviewed channel.

Frequently asked questions

How long is a typical sermorelin cycle?

Most adult protocols run 3 to 6 months before reassessment with labs and a symptom check. This isn't an FDA-set number since sermorelin's only approved adult use (branded as Geref) was discontinued by the manufacturer, not pulled for safety, leaving cycle length to individual prescriber judgment rather than a fixed label instruction.

Do you have to take breaks between sermorelin cycles?

Many prescribers build in a break, reasoning that the GH axis is naturally pulsatile and continuous stimulation for years hasn't been studied in adults. There's no controlled trial proving a break is necessary versus continuous dosing; it's a cautious default given the limited long-duration safety data, not a rule with strong direct evidence behind it.

How long does it take for sermorelin to start working?

Most prescribers wait 8 to 12 weeks before checking IGF-1, since sermorelin stimulates your own pituitary gradually rather than delivering GH directly, and single measurements of GH itself are too pulsatile to be useful. Checking labs earlier than 8 weeks usually just wastes a blood draw.

Is sermorelin as effective as HGH for the same cycle length?

No, not established as equivalent. HGH is FDA-approved for confirmed adult growth hormone deficiency with a much larger evidence base for that specific use. Sermorelin works through a different, indirect mechanism (stimulating your own pituitary) with a narrower, mostly older evidence base, so treat it as a different option, not a proven substitute.

What happened to Geref, the branded sermorelin product?

Geref was the FDA-approved brand of sermorelin, used for diagnostic GH deficiency testing and briefly for adult GHD management. The manufacturer discontinued it for business reasons; it wasn't withdrawn over a safety concern. That's a meaningfully cleaner regulatory history than most compounded peptides can point to.

Can you stay on sermorelin indefinitely without cycling off?

There's no long-term adult trial establishing what continuous, indefinite sermorelin use does over years. Most cautious prescribers avoid open-ended dosing and instead set defined cycles with lab checkpoints, precisely because that long-duration safety data doesn't exist yet for this specific therapy in adults.

What labs should be checked during a sermorelin cycle?

Baseline IGF-1 before starting and a repeat at 8 to 12 weeks is the minimum reasonable monitoring plan. IGF-1 is used as the standard proxy for GH axis activity because direct GH levels are too pulsatile to measure meaningfully in routine practice. Some providers add fasting glucose given the axis's link to insulin sensitivity.

Does stacking sermorelin with other peptides change how long a cycle should run?

Combining sermorelin with a GHRP or with tesamorelin is done in some protocols on the theory that two different GH-stimulating pathways compound the effect, but there's no established standard duration for stacked regimens, and combined long-term safety data is thinner than for either peptide alone.

What are the risks of running a sermorelin cycle too long?

Specific long-duration adult data for sermorelin is limited. A separate case report on long-term growth hormone axis stimulation described a rare musculoskeletal complication (cervical osteophyte-related dysphagia) in a long-term user, illustrating that sustained GH axis activity isn't automatically risk-free over years, even though this case wasn't sermorelin-specific.

Is compounded sermorelin legal, and does that affect cycle planning?

Yes, compounded sermorelin can be legally prescribed and dispensed under 21 U.S.C. 353a, using bulk substances FDA permits under 503A or 503B compounding rules. Because there's no FDA-approved adult label, cycle length and monitoring are set by your prescriber's protocol rather than by a standardized regulatory dosing schedule.

How do you know if a sermorelin cycle is actually working?

Compare IGF-1 before and after the cycle alongside a specific symptom you were tracking (sleep, recovery, energy), not a vague sense of feeling different. If IGF-1 hasn't moved and symptoms haven't changed by 3 months, that cycle likely isn't working and continuing without adjustment is a poor use of money.

What happens to your body after you stop a sermorelin cycle?

Because sermorelin stimulates your own pituitary rather than replacing GH, stopping means your pituitary returns to its prior baseline pulsatile pattern rather than crashing. There isn't strong human data tracking exactly how fast IGF-1 or symptoms revert after stopping, so expectations here should be held loosely.

Sources

1. PubMed, Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? (Clinical Interventions in Aging, 2006): Sermorelin's branded product Geref was approved for GH deficiency management before being discontinued, and its mechanism as a GHRH analog is described here.
2. PubMed, Sermorelin: a review of its use in diagnosis and treatment of children with idiopathic GHD (BioDrugs, 1999): Sermorelin's original FDA-approved use was diagnostic testing and treatment of pediatric growth hormone deficiency.
3. Cornell Law School Legal Information Institute, 21 U.S.C. 353a (pharmacy compounding): Compounded sermorelin is legally prescribed and dispensed under the federal pharmacy compounding statute, 21 U.S.C. 353a.
4. eCFR, 21 CFR 216.23, the 503A Bulks List: FDA maintains a list of bulk drug substances, including those relevant to peptides, that compounding pharmacies may legally use under section 503A.
5. FDA, Bulk drug substances nominated for use in compounding (current list): The list of substances permitted for compounding is periodically reviewed and updated by FDA as substances are nominated.
6. PubMed, Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research & Reviews, 2026): A 2026 review catalogs therapeutic peptide applications in orthopedics while flagging evidence gaps in the field.
7. PubMed, Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026): A 2026 review examined safety and efficacy data for approved and unapproved peptide therapies used in musculoskeletal injury and athletic performance contexts.
8. PubMed, A potentially effective drug for patients with recurrent glioma: sermorelin (Annals of Translational Medicine, 2021): A 2021 case report explored sermorelin as a potential treatment approach in recurrent glioma, a context distinct from wellness use.
9. PubMed, An antibody-free, ultrafiltration-based assay for detection of GHRHs in urine at low pg/mL concentrations (Journal of Pharmaceutical and Biomedical Analysis, 2022): Anti-doping laboratories have developed methods sensitive enough to detect GHRH-class peptides at low picogram-per-mL concentrations in urine.
10. PubMed, Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography-orbitrap MS (Journal of Pharmaceutical and Biomedical Analysis, 2026): Increasingly sensitive detection methods for GHRH analogs have been developed because synthetic versions have shown up outside legitimate prescribing contexts.
11. PubMed, Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum IGF-1 Levels (American Journal of Men's Health, 2017): A study found growth hormone secretagogue treatment raised serum IGF-1 levels in hypogonadal men, supporting IGF-1 as the standard monitoring marker.
12. PubMed, Operation Resistance: A snapshot of falsified antibiotics and biopharmaceutical injectables in Europe (Drug Testing and Analysis, 2016): A 2016 European surveillance study documented falsified biopharmaceutical injectables circulating through illegitimate distribution channels.
13. PubMed, Anterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report (Frontiers in Surgery, 2026): A 2026 case report described a rare musculoskeletal complication (cervical osteophyte-related dysphagia) in a long-term growth hormone user.
14. PubMed, Perinatal growth hormone physiology: effect of GH-releasing factor on maternal and fetal secretion (Journal of Clinical Endocrinology and Metabolism, 1990): GHRH-driven growth hormone secretion follows a naturally pulsatile pattern, a basic feature of how the axis is physiologically regulated.
15. FDA, Drugs@FDA: FDA-Approved Drug Products database: Recombinant HGH products are FDA-approved for specific adult indications including confirmed adult growth hormone deficiency, listed in the Drugs@FDA database.